KU Leuven researchers selected for COVID-19 therapeutics in IMI fast-track call

19 May 2020 | Network Updates | Update from KU Leuven
These updates are republished press releases and communications from members of the Science|Business Network

Europe's Innovative Medicines Initiative (IMI) selected 8 projects for funding from its fast-track call for proposals on coronavirus diagnostics and treatments. KU Leuven takes up a prominent role in the selected CARE project, involving research groups of Professors Johan Neyts, Isabelle Huys and Nico Vandaele. The KU Leuven Centre for Drug Design and Discovery (CD3) is also involved.

The goal of the CARE project is to deliver treatments for current as well as future coronavirus outbreaks. To do this, they will identify candidates among existing drugs that could be effective as treatments for the COVID-19 pandemic, and develop new drugs specially designed to tackle the SARS-CoV-2 virus. After extensive testing in the laboratory, the project will advance the most promising drug candidates to clinical trials in humans.

Read more on the IMI website.

This article was first published on 14 May by KU Leuven.

Never miss an update from Science|Business:   Newsletter sign-up